Target Name: USP15
NCBI ID: G9958
Review Report on USP15 Target / Biomarker Content of Review Report on USP15 Target / Biomarker
USP15
Other Name(s): Ubiquitin specific peptidase 15, transcript variant 2 | USP15 variant 1 | UBP15_HUMAN | Ubiquitin specific peptidase 15 | Deubiquitinating enzyme 15 | ubiquitin-specific-processing protease 15 | UNPH-2 | Ubiquitin specific protease 15 | ubiquitin specific peptidase 15 | KIAA0529 | USP15 variant 2 | ubiquitin thioesterase 15 | Ubiquitin carboxyl-terminal hydrolase 15 (isoform 1) | ubiquitin thiolesterase 15 | Ubiquitin thiolesterase 15 | Unph-2 | deubiquitinating enzyme 15 | Ubiquitin carboxyl-terminal hydrolase 15 | Ubiquitin thioesterase 15 | Ubiquitin carboxyl-terminal hydrolase 15 (isoform 2) | Unph4 | UNPH4 | Ubiquitin specific peptidase 15, transcript variant 1 | Ubiquitin-specific-processing protease 15

USP15: A Potential Drug Target for Various Diseases

USP15, also known as Ubiquitin specific peptidase 15, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the ubiquitin proteasome, a complex of enzymes that break down other proteins into smaller pieces. USP15 is unique among its family because it is specifically involved in the degradation of Ubiquitin, a protein that is found in nearly all cells and plays a critical role in the regulation of a wide range of cellular processes.

Recent studies have identified USP15 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because USP15 has been shown to be highly expressed in many types of cancer, and because it is involved in the regulation of cellular processes that are often disrupted in these conditions.

One of the key reasons why USP15 is thought to be a good candidate for drug targeting is that it is highly expressed in a variety of tissues and has been shown to be involved in a wide range of cellular processes. For example, studies have shown that USP15 is highly expressed in a variety of cancer tissues, including breast cancer, lung cancer, and colorectal cancer. This suggests that it may be a useful target for these types of diseases.

Another reason why USP15 is a potential drug target is that it is involved in the regulation of processes that are often disrupted in many types of neurodegenerative diseases. For example, studies have shown that USP15 is involved in the degradation of the neurotransmitter tau, which is often found in the brains of people with Alzheimer's disease. This suggests that USP15 may be a useful target for treatments for these conditions.

In addition to its potential role as a drug target, USP15 has also been shown to be involved in a number of other cellular processes that are important for human health. For example, it is involved in the regulation of the immune system, and has been shown to play a role in the development of autoimmune disorders. It is also involved in the regulation of cell division, and has been shown to play a role in the development of cancer.

Overall, USP15 is a protein that is highly expressed in a variety of tissues and is involved in a wide range of cellular processes. As a result, it is a promising candidate for drug targeting and may be useful for a variety of diseases. Further research is needed to fully understand the role of USP15 in human health and to develop effective treatments.

Protein Name: Ubiquitin Specific Peptidase 15

Functions: Hydrolase that removes conjugated ubiquitin from target proteins and regulates various pathways such as the TGF-beta receptor signaling, NF-kappa-B and RNF41/NRDP1-PRKN pathways (PubMed:21947082, PubMed:22344298, PubMed:24852371, PubMed:16005295, PubMed:17318178, PubMed:19826004, PubMed:19576224). Acts as a key regulator of TGF-beta receptor signaling pathway, but the precise mechanism is still unclear: according to a report, acts by promoting deubiquitination of monoubiquitinated R-SMADs (SMAD1, SMAD2 and/or SMAD3), thereby alleviating inhibition of R-SMADs and promoting activation of TGF-beta target genes (PubMed:21947082). According to another reports, regulates the TGF-beta receptor signaling pathway by mediating deubiquitination and stabilization of TGFBR1, leading to an enhanced TGF-beta signal (PubMed:22344298). Able to mediate deubiquitination of monoubiquitinated substrates, 'Lys-27'-, 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains (PubMed:33093067). May also regulate gene expression and/or DNA repair through the deubiquitination of histone H2B (PubMed:24526689). Acts as an inhibitor of mitophagy by counteracting the action of parkin (PRKN): hydrolyzes cleavage of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains attached by parkin on target proteins such as MFN2, thereby reducing parkin's ability to drive mitophagy (PubMed:24852371). Acts as an associated component of COP9 signalosome complex (CSN) and regulates different pathways via this association: regulates NF-kappa-B by mediating deubiquitination of NFKBIA and deubiquitinates substrates bound to VCP (PubMed:16005295, PubMed:17318178, PubMed:19826004, PubMed:19576224). Involved in endosome organization by mediating deubiquitination of SQSTM1: ubiquitinated SQSTM1 forms a molecular bridge that restrains cognate vesicles in the perinuclear region and its deubiquitination releases target vesicles for fast transport into the cell periphery (PubMed:27368102). Acts as a negative regulator of antifungal immunity by mediating 'Lys-27'-linked deubiquitination of CARD9, thereby inactivating CARD9 (PubMed:33093067)

The "USP15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA